These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 36845453)
1. Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye. Maggio E; Alfano A; Mete M; Pertile G Case Rep Ophthalmol; 2022; 13(3):736-743. PubMed ID: 36845453 [TBL] [Abstract][Full Text] [Related]
2. Changes in the uninjected contralateral eye after intravitreal brolucizumab for exudative age-related macular degeneration. Mora P; Bellucci C; Radice LM; Manzotti F; Gandolfi S Eur J Ophthalmol; 2024 Jan; 34(1):NP104-NP107. PubMed ID: 37424299 [TBL] [Abstract][Full Text] [Related]
3. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization. Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients. Mishra SK; Kumar P; Khullar S; Joshi A; Sati A; Kumar SV; Unni D; Kumar A Int J Retina Vitreous; 2022 Jul; 8(1):51. PubMed ID: 35902887 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes. Mun Y; Park KH; Park SJ; Woo SJ PLoS One; 2021; 16(6):e0252006. PubMed ID: 34111133 [TBL] [Abstract][Full Text] [Related]
6. Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration. Mehta N; Fong RD; Wilson M; Moussa K; Emami-Naeini P; Moshiri A; Yiu G; Park SS Clin Ophthalmol; 2023; 17():657-665. PubMed ID: 36880020 [TBL] [Abstract][Full Text] [Related]
7. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066 [TBL] [Abstract][Full Text] [Related]
8. Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye. Hahn P Clin Ophthalmol; 2014; 8():2129-31. PubMed ID: 25378900 [TBL] [Abstract][Full Text] [Related]
9. Short-term Efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-Naive Exudate Age-related Macular Degeneration: A Multicenter Study. Kim J; Lee SJ; Park TK; Sun HJ; Kim HD; Cho IH; Han JW; Choi KS Korean J Ophthalmol; 2023 Oct; 37(5):365-372. PubMed ID: 37562440 [TBL] [Abstract][Full Text] [Related]
10. Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study. Ueda-Consolvo T; Tanigichi A; Numata A; Oiwake T; Nakamura T; Ishida M; Yanagisawa S; Hayashi A Graefes Arch Clin Exp Ophthalmol; 2023 Feb; 261(2):345-352. PubMed ID: 35947181 [TBL] [Abstract][Full Text] [Related]
11. First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration. Abdin AD; Aljundi W; El Jawhari K; Suffo S; Weinstein I; Seitz B Front Pharmacol; 2022; 13():860784. PubMed ID: 35721125 [No Abstract] [Full Text] [Related]
12. Efficacy and safety of brolucizumab for serous drusenoid pigment epithelium detachment non-responder to bevacizumab and aflibercept. Saitta A; D'Eliseo LA; D'Eliseo D Eur J Ophthalmol; 2023 Nov; 33(6):NP109-NP112. PubMed ID: 36448189 [TBL] [Abstract][Full Text] [Related]